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Summary
Chronic granulomatous disease (CGD) is a hereditary
disorder of host defense due to absent or decreased ac-
tivity of phagocyte NADPH oxidase. The X-linked form
of the disease derives from defects in the CYBB gene,
which encodes the 91-kD glycoprotein component
(termed “gp91-phox”) of the oxidase. We have identified
the mutations in the CYBB gene responsible for X-linked
CGD in 131 consecutive independent kindreds. Screen-
ing by SSCP analysis identified mutations in 124 of the
kindreds, and sequencing of all exons and intron bound-
ary regions revealed the other seven mutations. We de-
tected 103 different specific mutations; no single mu-
tation appeared in more than seven independent
kindreds. The types of mutations included large and
small deletions (11%), frameshifts (24%), nonsense mu-
tations (23%), missense mutations (23%), splice-region
mutations (17%), and regulatory-region mutations
(2%). The distribution of mutations within the CYBB
gene exhibited great heterogeneity, with no apparent mu-
tational hot spots. Evaluation of 87 available mothers
revealed X-linked carrier status in all but 10. The het-
erogeneity of mutations and the lack of any predominant
genotype indicate that the disease represents many dif-
ferent mutational events, without a founder effect, as is
expected for a disorder with a previously lethal
phenotype.
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Introduction
Chronic granulomatous disease (CGD) is a hereditary
disorder of host defense due to defective activity of a
phagocyte NADPH oxidase that generates superoxide
and related toxic oxygen metabolites necessary for mi-
crobial killing (Curnutte et al. 1994). Patients usually
present early in life, with multiple, sometimes fatal, py-
ogenic infections (Berendes et al. 1957; Forrest et al.
1988; Mouy et al. 1989; Finn et al. 1990); in less severe
cases the diagnosis may become apparent only in ado-
lescence or adulthood (Schapiro et al. 1991).
The NADPH-oxidase enzyme system responsible for
superoxide generation forms a small transmembrane
electron-transport system that results in the oxidation
of NADPH on the cytoplasmic surface and the gener-
ation of superoxide on the outer surface of the
membrane, which in turn becomes the inner surface of
the phagosome when invagination occurs during phago-
cytosis. Analysis of the defects responsible for CGD has
helped to define many of the biochemical and molecular
features of this complex system. Individual protein con-
stituents and their genes have been identified and cloned
(Royer-Pokora et al. 1986; Nunoi et al. 1988; Volpp et
al. 1988; Dinauer et al. 1990; Leto et al. 1990); analysis
of protein andmembrane interactions are nowbeginning
to provide a picture of oxidase organization and assem-
bly during phagocyte activation (DeLeo and Quinn
1996; Leusen et al. 1996).
The terminal electron donor to oxygen is a unique,
low-midpoint–potential flavocytochrome, termed “cy-
tochrome b558” because of its spectral peak at 558 nm.
The heterodimeric molecule consists of a 91-kD glyco-
protein, termed “gp91-phox” (phagocyte oxidase), and
a 22-kD nonglycosylated polypeptide, termed “p22-
phox” (Royer-Pokora et al. 1986; Parkos et al. 1988;
Curnutte 1993). The CYBB gene (GenBank accession
number X04011), which encodes gp91-phox, was one
of the first to be identified by positional cloning (Royer-
Pokora et al. 1986), following chromosomal localization
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Table 1
Deletion Mutations in the CYBB Gene
KINDRED
NUMBER
MUTATION
CGD PHENOTYPEa
X-CGDBASE
NUMBERPosition
Size/Affected
Amino Acid(s)
1 Multigene k30 kb X910  DMD 
McLeod
A0119
2 Multigene k30 kb X910  McLeod A0034
3 Multigene k30 kb X910  McLeod
4 Multigene k30 kb X910  McLeod A0169
5 Multigene k30 kb X910  McLeod A0201
6 Multigene k30 kb X910  McLeod A0167
7 Multigene k30 kb X910  ?McLeod
8 Exons 11–13 x4.3 kb/439 Ile–570
Phe deleted
X910 A0172
9 Exon 4 2 kb X910
10 Exon 1 ND O2
 production  0;
cytochrome b, ND
11 Exon 13 1123 nt/530 Thr–570
Phe deletedb
X910 A0203
12 Exon 13 (nt
1694–1724)
31 nt X910 A0155
13 Exon/intron 5 (nt
494 to intron)
6 nt X910 A0181
14 Exon/intron 9 (nt
1162 to intron)
4 nt (AAgt)/splicing
defect
X910 A0156
15 Exon 9 (nt 954–6) 3 nt/315 Lys deleted X91 A0163
NOTE.—ND  not determined.
a “X” indicates the X-linked mode of inheritance; “91” indicates that the gp91-phox component
of the phagocyte oxidase is affected; and the superscript symbols indicate an undetectable (“0”) or
diminished (“”) level of that component protein (Curnutte et al. 1994). “DMD”denotesDuchenne
muscular dystrophy; “McLeod” denotes the McLeod phenotype (Redman and Marsh 1993); and
“?McLeod” denotes possible McLeod phenotype, not rigorously evaluated.
b Previously published by Royer-Pokora et al. (1986).
to Xp21.1 (Baehner et al. 1986); it encompasses 13 ex-
ons spanning ∼30 kb of genomic DNA (Skalnik et al.
1991). CGD kindreds with defects in the gp91-phox
component thus show X-linked inheritance, and in most
cases cytochrome b558 is reduced or absent from their
phagocytes (Segal et al. 1983). Recent studies have
probed indirectly the structure of the glycoprotein mol-
ecule and its molecular interactions (DeLeo and Quinn
1996; Leusen et al. 1996), but the locations of its func-
tional domains have been inferred mostly by sequence
homology rather than by direct demonstration.
Diverse molecular defects producing X-linked CGD
have been identified within the coding region and introns
of the CYBB gene (De Saint–Basile et al. 1988; Frey et
al. 1988; Dinauer et al. 1989; Bolscher et al. 1991;
Schapiro et al. 1991; de Boer et al. 1992; Rabbani et al.
1993; Ariga et al. 1994a, 1994b, 1995; Leusen et al.
1994; Newburger et al. 1994a, 1994b; Azuma et al.
1995; Bu-Ghanim et al. 1995; Cross et al. 1995); most
have been reported in single cases or small series. Roos
et al. (1996b) have reviewed a large collection of mu-
tations associated with both X-linked and autosomal
recessive forms of CGD. Forms of mutations causing X-
linked CGD have included large multigene deletions,
smaller deletions and insertions, missense and nonsense
substitutions, and splicing defects. This study reports the
mutations identified in 131 consecutive X-linked CGD
kindreds studied at the participating institutions.
Subjects, Material, and Methods
Subjects
Blood samples were obtained from CGD patients and
family members who were referred to the investigators
or who were sent to the CGD reference laboratories at
the Scripps Research Institute or Stanford University
Medical School. Procedures and consent forms were ap-
proved by the Committees on the Protection of Human
Subjects in Research at the Scripps Research Institute,
Stanford University Medical School, Indiana University
Medical School, and University of Massachusetts Med-
ical Center. Most (103/131) of the mutations have been
entered into the X-CGDbase database (Roos et al.
1996a); accession numbers are indicated in tables 1–6.
The X-linked nature of CGD was established in these
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kindreds by an algorithmic series of biochemical and
molecular tests of both patients and available maternal
relatives, as described below. This approach, which in-
cluded genomic DNA sequencing, was designed to min-
imize (but could not eliminate completely) false-negative
results for carrier detection. In male patients with una-
vailable or noncarrier mothers, X-linked CGDwas dem-
onstrated by biochemical and molecular identification of
a defect in the gp91-phox glycoprotein and the CYBB
gene.
In all 38 non–X-linked CGD kindreds studied during
the same time period, defects in the genes encoding p47-
phox, p67-phox, or p22-phox were identified positively
by western blotting for cytosolic oxidase components,
complementation in cell-free oxidase assays (Curnutte
et al. 1987), and DNA sequencing of the affected genes.
Thus, it is unlikely that any X-linked defect was not
detected because of misclassification as an unidentified
form of autosomal recessive CGD.
NADPH Oxidase
Cytochrome b558 content was measured by dithionite
reduction and difference spectroscopy, as described else-
where (Woodman et al. 1995). NADPH-oxidase activity
was determined by spectrophotometric assay of super-
oxide dismutase–inhibitable cytochrome c reduction or
by flow cytometry using dichlorofluorescein or dihy-
drorhodamine indicators, as described elsewhere (Wood-
man et al. 1995).
SSCP Analysis
Genomic DNA was extracted from peripheral blood
(Maniatis et al. 1990) and was analyzed by SSCP, as
described elsewhere (Orita et al. 1989a, 1989b), by use
of two-stage PCR utilizing 18–27-bp oligonucleotide
primers (sequences available by request) with 0.1 mg
genomic DNA, followed by nested PCR with primers
end labeled with 32P or 33P. The resultant labeled PCR
products were visualized by PAGE and autoradiography.
SSCP analysis was performed on the 5′ flanking region
and on all 13 exons of the gp91-phox gene. Only 7 of
the 131 kindreds had mutations undetectable by SSCP;
these were identified subsequently by sequencing of the
complete set of PCR amplicons.
DNA Sequencing
Genomic DNA was isolated from peripheral blood
leukocytes by use of standard methods (Maniatis et al.
1990) and was amplified by PCR using synthetic oli-
gonucleotide primers designed to amplify the 5′ flanking
region or each of the 13 exons of the CYBB gene. Al-
ternatively, coding-region segments were amplified from
cDNA prepared by reverse transcription (Pharmacia
First-Strand cDNA Synthesis Kit) of mononuclear-cell
RNA, prepared by differential precipitation from gua-
nidine HCl (Ginsburg et al. 1985). Amplified segments
were sequenced directly or were subcloned into pUC19
or related plasmids. Bidirectional dideoxy sequencing
was performed by standard methods (Maniatis et al.
1990). For sequence alterations that were not self-evi-
dent as causes of a CGD phenotype, such as missense
and splicing mutations, we compared SSCP patterns or
DNA sequences from 200 normal X chromosomes, to
diminish the likelihood that the change represented a
polymorphism.
Results
Mutations in the gene encoding gp91-phox were de-
tected in all 131 kindreds, with abnormal migration dur-
ing SSCP analysis evident in 124 kindreds. Tables 1–6
present the findings, organized by type of mutation. For
most cases, the source of DNA for study was the pre-
senting CGD patient; in several families, the propositus
was no longer living, and the mutation was detected by
analysis of genomic DNA from the carrier mother or
from an affected brother. All available members of each
family were studied (412 individuals altogether), and the
mutations were found to segregate with CGD disease or
carrier status, in all cases. For extended kindreds with
several families (or families with multiple members af-
fected), only a single representative is listed. Thus, the
“shared genotype” notation indicates no known rela-
tionship between the affected kindreds.
Deletions of x3 nt were found in 15 (11%) of the
131 kindreds and formed a very heterogeneous group
(table 1). Several of these deletions removed the entire
gene; shared genotypes cannot be ruled out, because
their termini have not been mapped. The phenotype in
kindred 1 included CGD, McLeod syndrome, and Du-
chenne muscular dystrophy, as described elsewhere in
other kindreds (De Saint–Basile et al. 1988; Frey et al.
1988), and indicated a very large multigenic deletion
sufficient in size to be visualized by chromosome-band-
ing studies. At least five other patients also showed the
McLeod phenotype (Densen et al. 1981). This linkage
is consistent with the known X-chromosome map po-
sitions of the X-linked CGD and McLeod loci (MIM
306400 and 314850, respectively) (Nagaraja et al.
1997). At the other end of the spectrum of these mu-
tations, very small in-frame deletions caused interstitial
removal of from 1 (number 15) to 132 (number 8) amino
acids. In the former patient, the deletion of a single
amino acid, lysine at position 315, resulted in the re-
tention of partial oxidase function, with 19% normal
superoxide-generating activity and 13% normal levels
of cytochrome b, which is an example of the X91 phe-
notype in the biochemical classification of CGD (Cur-
nutte 1988). As was expected, all others tested had no
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Table 2
Frameshift Mutations in the CYBB Gene
KINDRED
NUMBER
MUTATION CGD PHENOTYPEa
SHARED
GENOTYPE
X-CGDBASE
NUMBERPosition Nucleotide Change
Termination
Site
Superoxide
Production
(% Normal)
Cytochrome b
Content
(% Normal)
1 Exon 3 169 C insertion Exon 5 0 0 A0160
2 Exon 3 207 G insertion Exon 4 0 0 A0196
3 Exon 4 307 A deletion Exon 4 0 0 A0097
4 Exon 5 366 A deletion Exon 5 0 ND A0103
5 Exon 5 454–5 CArT Exon 5 0 ND A0111
6 Exon 5 455 A insertion Exon 5 0 0 A0139
7 Exon 6 607 A deletion Exon 6 ND 0
8 Exon 7 713–4 AG deletion Exon 7 0 ND A0120
9 Exon 7 728–32 deletion Exon 7 0 0 A0117
10 Exon 7 749 A insertion Exon 8 NL NL A
11 Exon 7 749 A insertion Exon 8 0 0 A A0121
12 Exon 7 749 A insertion Exon 8 0 0 A A0126
13 Exon 7 749 A insertion Exon 8 0 ND A A0146
14 Exon 7 749 A insertion Exon 8 0 0 A A0162
15 Exon 7 749 A insertion Exon 8 NL NL A A0170
16 Exon 7 749 A insertion Exon 8 0 0 A A0189
17 Exon 7 764 G deletion Exon 8 NL NL A0195
18 Exon 7 768 A insertion Exon 8 0 0 A0128
19 Exon 9 935 CCTTTCA insertion,
947–9 deletion
Exon 9 0 ND
20 Exon 9 975 G deletion Exon 9 0 0 A0118
21 Exon 9 1050 T deletion Exon 10 0 0 B A0129
22 Exon 9 1050 T deletion Exon 10 0 ND B A0161
23 Exon 10 1246 G insertion Exon 10 ND ND A0144
24 Exon 10 1283 G deletion Exon 10 NL NL
25 Exon 10 1325–6 AGrT Exon 12 0 0 A0091
26 Exon 11 1361 C deletion Exon 11 NL NL A0192
27 Exon 11 1426 G deletion Exon 12 0 0 A0092
28 Exon 11 1467 G deletion Exon 12 NL NL A0165
29 Exon 11 1467 T insertion Exon 12 ND ND A0184
30 Exon 12 1475 C deletion Exon 12 0 ND A0114
31 Exon 12 1539–40 TT deletion Exon 12 0 ND A0143
32 Exon 13 1634 insertion of 4 nt Exon 13 0 0 A0183
a ND  not determined; NL  patient not living.
detectable cytochrome b protein or oxidase activity,
termed the “X910” phenotype. In the X91 phenotype,
found in patients with other mutations, described below,
granulocytes have normal levels of cytochrome b but do
not have NADPH-oxidase enzyme activity.
Smaller, usually 1-nt deletions and insertions disrupted
the normal reading frame for translation in 32 (24%)
of the 131 kindreds studied. As noted in other series
(Roos et al. 1996b), such mutations are a quite common
cause of CGD. The frameshift mutations (table 2) cre-
ated nonsense codons within two exons downstream of
the mutation and, hence, X910 phenotypes due to non-
functional, truncated proteins that are undetectable by
spectroscopic or immunological methods of analysis.
Seven kindreds shared the same frameshift mutation due
to insertion of adenosine at nt 749, which is one of six
consecutive adenosine nucleotides that may be particu-
larly subject to errors in recombination. The precise po-
sition of a mutational event within a tract of identical
nucleotides cannot be determined; thus, all of these mu-
tations were assigned to the last nucleotide of the series,
where the functional frameshift occurs.
Direct mutation from a coding to a nonsense codon
(table 3) also caused an X910 phenotype in all patients
tested. These nonsense mutations also were common:
they were found in 30 (23%) of the 131 kindreds. In-
terestingly, many kindreds shared their mutation with at
least one other family. Additional genetic analysis would
be necessary to determine whether these kindreds share
a more extensive genetic background, owing to common
founders, or whether they represent coincidental parallel
mutations. Of the seven patients (numbers 1, 6, 7, 13,
19, 23, and 28; table 3) analyzed by northern blot for
CYBB transcripts, four patients (numbers 13, 19, 23,
and 28) showed reduced or undetectable levels of
mRNA, consistent with the destabilizing effects of non-
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Table 3
Nonsense Mutations in the CYBB Gene
KINDRED
NUMBER
MUTATION
SHARED
GENOTYPE
X-CGDBASE
NUMBERPosition Nucleotide Change Termination Sitea
1 Exon 1 24 GrA 4 Trp A0108
2 Exon 3 229 CrT 73 Arg A A0188
3 Exon 3 229 CrT 73 Arg A
4 Exon 4 283 CrT 91 Arg B A0149
5 Exon 4 283 CrT 91 Arg B A0178
6 Exon 5 400 CrT 130 Arg A0113
7 Exon 5 468 TrA 152 Tyr A0124
8 Exon 5 481 CrT 157 Arg C A0095
9 Exon 5 481 CrT 157 Arg C A0098
10 Exon 5 481 CrT 157 Arg C A0152
11 Exon 5 481 CrT 157 Arg C A0177
12 Exon 6 567 CrA 185 Cys A0182
13 Exon 7 688 CrTb 226 Arg D A0132
14 Exon 7 688 CrT 226 Arg D A0150
15 Exon 7 688 CrT 226 Arg D
16 Exon 7 748 CrT 246 Gln E A0122
17 Exon 7 748 CrT 246 Gln E A0186
18 Exon 8 827 GrA 272 Trp A0099
19 Exon 8 880 CrT 290 Arg F A0145
20 Exon 8 880 CrT 290 Arg F A0159
21 Exon 8 880 CrT 290 Arg F A0194
22 Exon 8 880 CrT 290 Arg F A0198
23 Exon 9 1018 GrT 336 Glu A0087
24 Exon 9 1151 GrA 380 Trp A0086
25 Exon 9 1151 GrA 380 Trp A0174
26 Exon 11 1332 CrA 440 Tyr A0151
27 Exon 11 1341 GrA 443 Trp G
28 Exon 11 1341 GrA 443 Trp G A0168
29 Exon 11 1370 GrA 453 Trp
30 Exon 12 1531 CrT 507 Gln A0116
a Former amino acid.
b Previously published by Newburger et al. (1994a).
sense mutations (Maquat 1995). The locations of these
mutations were all 3′ to the positions of the mutations
that did not affect mRNA levels, unlike the predomi-
nantly upstream positions of destabilizing nonsense co-
dons in transcripts encoding b-globin, adenine phos-
phoribosyltransferase, and triose phosphate isomerase
(Maquat 1995; Kessler and Chasin 1996).
Missense mutations (table 4) resulted from 1- or 2-nt
changes that altered the DNA sequence to encode a dif-
ferent amino acid and were found in 30 (23%) of the
131 kindreds. As expected, several showed X91 phe-
notypes, indicating partial preservation of both cyto-
chrome b levels and oxidase function. Two unrelated
kindreds (numbers 23 and 24; table 4) had the same
mutation, which led to substitution of histidine for pro-
line at position 415, resulting in X91 phenotypes with
complete preservation of cytochrome b but absence of
oxidase-enzyme activity. Thus, the 415 proline residue
appears to be essential for function but not for protein
stability. The substitution of arginine for cysteine at res-
idue 537 (number 30; table 4) produced a similar phe-
notype, indicating that this cysteine is functionally, but
not structurally, essential. Four other mutations, found
in five unrelated kindreds (numbers 6, 7, 14, 16, and
18; table 4), produced an amino acid substitution that
greatly reduced both cytochrome b content and oxidase
activity. Such X91 phenotypes indicate positions in the
gp91-phox molecule that may be slightly permissive for
structural alterations, but these changes greatly desta-
bilize the protein molecule. One patient (number 18;
table 4) had an additional base change (1102GrC) that
also has been found in an unaffected individual and
therefore appears to be a known rare polymorphism
(Kuribayashi et al. 1996).
Mutations in or near splice-junction sites (table 5)
produced CGD by interfering with mRNA processing
and were found in 22 (17%) of the 131 families. Most
occurred at the splice junction and, in those tested, re-
sulted in an X910 phenotype with no NADPH-oxidase
expression, as in most previously reported splicing mu-
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Table 4
Missense Mutations in the CYBB Gene
KINDRED
NUMBER Position
MUTATION CGD PHENOTYPEa
SHARED
GENOTYPE
X-CGDBASE
NUMBER
Nucleotide
Change
Amino Acid
Change
Superoxide
Production
(% Normal)
Cytochrome b
Content
(% Normal)
1 Exon 2 70 GrC 20 GlyrArg 0 0 A0136
2 Exon 3 174 GrC 54 ArgrSer 0 100 A0133
3 Exon 3 187 TrC 59 CysrArg 0 0 A0175
4 Exon 5 368 ArG 119 HisrArg 0 ND A
5 Exon 5 368 ArG 119 HisrArg 0 ND A A0153
6 Exon 5 478 GrA 156 AlarThr 3 ND B A0137
7 Exon 5 478 GrA 156 AlarThr 2 3 B A0187
8 Exon 6 639 TrA 209 HisrGln 0 0 A0125
9 Exon 6 676 CrA 222 HisrAsn ND ND
10 Exon 6 676 CrT 222 HisrTyr ND ND
11 Exon 6 677 ArG 222 HisrArg 0 ND
12 Exon 6 679–80 GGrTT 223 GlyrLeu ND ND A0109
13 Exon 7 742 TrC 244 CysrArg 0 ND A0171
14 Exon 9 937 GrA 309 GlurLys 4 17 A0101
15 Exon 9 977 GrA 322 GlyrGlu NL NL
16 Exon 9 985 ArT 325 IlerPhe 4 5
17 Exon 9 1009 TrC 333 SerrPro NL NL A0200
18 Exon 9 1028 CrA 339 ProrHis 0 20 A0096
19 Exon 9 1079 GrC 356 ArgrPro ND ND
20 Exon 10 1226 TrG 405 MetrArg 0 ND A0142
21 Exon 10 1234 GrA 408 GlyrArg 0 ND A0157
22 Exon 10 1235 GrA 408 GlyrGlu 0 ND A0190
23 Exon 10 1256 CrAb 415 ProrHis 0 100 C A0107
24 Exon 10 1256 CrA 415 ProrHis 0 100 C
25 Exon 10 1256 CrT 415 ProrLeu ND ND A0112
26 Exon 10 1276 TrC 422 SerrPro NL NL A0202
27 Exon 11 1369 TrC 453 TrprArg 0 ND
28 Exon 12 1560 GrT 516 TrprCys 0 ND A0094
29 Exon 13 1613 TrA 534 ValrAsp NL NL A0147
30 Exon 13 1621 TrC 537 CysrArg 0 100 A0199
a ND  not determined; NL  patient not living.
b Previously published by Dinauer et al. (1989).
tations in X-linked CGD (de Boer et al. 1992). However,
in four kindreds (numbers 1, 8, 9, 10, 11, and 14; table
5), retention of a small proportion of normal splicing
allowed limited preservation of oxidase activity (au-
thors’ unpublished data). One of these kindreds (number
1; table 5) has proved uniquely responsive to treatment
with interferon-g, with virtually complete restoration of
superoxide-generating activity in vitro and in vivo, at
least in part owing to increased levels of normal tran-
scripts (Ezekowitz et al. 1987, 1988; Condino-Neto et
al. 1997). The exon 5 base change in kindred 14 also
predicts themissense substitution 161LysrArg; the other
exonic splicing mutations (numbers 8–11, shared ge-
notype A; table 5) do not change the translation of the
affected alanine codon. The mutation at 8 nt from the
3′ end of intron 3 creates an alternative AG dinucleotide
splice-acceptor site; cDNA sequencing revealed incor-
poration of the downstream nucleotides into exon 4,
leading to a frameshift with termination in that exon.
As previously reported, two kindreds with neighbor-
ing regulatory-region mutations (table 6) have an unu-
sual form of X91 CGD with absent oxidase activity in
90%–95% of their neutrophils but normal levels in the
remainder (Newburger et al. 1994b; Woodman et al.
1995). The mutations disrupt the binding site for a newly
identified transcription factor, HAF-1 (Eklund and Skal-
nik 1995), and indicate its probable importance for ex-
pression of the CYBB gene.
All available maternal relatives were screened for X-
linked CGD carrier status, either by genomic DNA anal-
ysis (SSCP or sequencing of the exon known to be af-
fected) or by examination of peripheral blood granu-
locytes for a subpopulation of cells with the CGD
biochemical phenotype due to random inactivation of
the normal X chromosome. Of 87 mothers tested, only
10 (11%) did not reveal X-linked carrier status. Ten of
25 maternal grandmothers and one of three maternal
great-grandmothers were not carriers. There were no
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Table 5
Splicing Mutations in the CYBB Gene
KINDRED
NUMBER
MUTATION
CGD
PHENOTYPEa,b
SHARED
GENOTYPE
X-CGDBASE
NUMBERPosition Nucleotide Change Splicing Producta
1 Intron 1, 5′ splice site gtaagtrgtaagc Decreased mRNA X91 A0134
2 Intron 2, 3′ splice site agrgg Exon 3 deletion X910 A0105
3 Intron 2, 5′ splice site gtrtt ND X910 A0154
4 Intron 2, 5′ splice site gtrgg ND NL
5 Intron 2, 5′ splice site gtrat ND X910 A0131
6 Intron 2, 5′ splice site gtrtt Exon 2 deletion X910 A0138
7 Exon 3, 2 nt from 3′ splice 263 C deletion Multiple X910 A0110
8 Exon 3, 1 nt from 3′ splice 264 GrA ND X91 A A0100
9 Exon 3, 1 nt from 3′ splice 264 GrA Exon 3 deletion
 normal
X91 A
10 Exon 3, 1 nt from 3′ splice 264 GrA Exon 3 deletion X91 A A0193
11 Exon 3, 1 nt from 3′ splice 264 GrA ND X91 A A0127
12 Intron 3, 8 nt from 3′ splice aatccaaagragtccaaag Alternative splicing X910
13 Intron 3, 5′ splice site gtaagrgtaac ND X910 A0148
14 Exon 5 494 ArG Multiple X91 A0179
15 Intron 5, 5′ splice site gtrgc ND X910 A0164
16 Intron 5, 5′ splice site gtrtt ND X910 A0115
17 Intron 5, 5′ splice site gtaagrgtaaa ND ND A0140
18 Intron 6, 5′ splice site Deletion: gtgagtrgt ND X910 A0106
19 Intron 6, 5′ splice site gtgagtrgtgaga ND X910
20 Intron 7, 3′ splice site agraa NL NL
21 Intron 10, 3′ splice site tcagrtcac ND X910
22 Intron 10, 5′ splice site gtrat NL NL
a ND  not determined; NL  patient not living.
b “X” indicates the X-linked mode of inheritance; “91” indicates that the gp91-phox component of the phagocyte oxidase is affected; and
the superscript symbols indicate an undetectable (“0”) or diminished (“”) level of that component protein (Curnutte et al. 1994).
Table 6
Regulatory-Region Mutations in the CYBB Gene
KINDRED
NUMBER
MUTATION
CGD
PHENOTYPEa
X-CGDBASE
NUMBERPosition
Nucleotide
Change
1 5′ flank 57 arc X91 A0089
2 5′ flank 55 trc X91 A0166
a Variant phenotype with heterogeneous distribution of oxidase ac-
tivity (see text).
significant differences in carrier-detection rates between
types of mutations.
Discussion
We have identified mutations in the CYBB gene that
are responsible for X-linked CGD in 131 consecutive
kindreds examined in a multicenter study. Screening by
SSCP identified abnormalities, defined by genomic DNA
sequencing, in 124 of the kindreds. In an additional 7
kindreds, sequencing of all exons and intron boundary
regions revealed mutations not detected by SSCP.Within
the 131 kindreds, we detected 103 different specific mu-
tations; no mutation appeared in 17 independent kin-
dreds, and most shared genotypes occurred in only 2 or
3 kindreds. The mutations reported in this study, along
with those identified by an international group of in-
vestigators, recently have been compiled by Roos et al.
(1996a) into a computerized database, X-CGDbase.
The range of mutations identified in the present study
spanned nearly all types of mechanisms by which genetic
change can disrupt gene expression. The most common
forms of mutation were small deletions or insertions re-
sulting in frameshifts (32 kindreds) and single-base
changes resulting in nonsense (30 kindreds) or missense
(30 kindreds) codons. Of the nonsense mutations, nearly
two-thirds were CrT transitions, of which 16 of 19
occurred at CG dinucleotides. The predominance of such
mutations has been reported in the factor VIII gene
(Youssoufian et al. 1988) and others; these CrT mu-
tations probably represent spontaneous deamination of
methylated cytosines in genomic DNA. Unlike previous
studies of the factor VIII gene, our data do not show a
similar distribution of base changes in missense
mutations.
At least 6 of the 15 deletion mutations were large
enough to affect the adjacent McLeod gene (XK). Clin-
ically, the phenotype includes compensated hemolysis,
acanthocytic erythrocyte morphology, and eventual neu-
rological symptoms, including areflexia, dystonia, and
choreiform movements (Redman and Marsh 1993). The
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Figure 1 Schematic representation of the gp91-phox protein molecule. Sites of missense mutations are identified by the number of the
affected amino acid, and types of mutation are indicated by symbols (as defined in the key [bottom right]). The shaded regions between amino
acids 403 and 546 represent the putative NADPH-binding site, and the stippled region between amino acids 335 and 360 represents the putative
FAD-binding site (Segal et al. 1992). “CHO” indicates a glycosylation site.
McLeod phenotype is defined hematologically by absent
erythrocyte Kx protein and diminished levels of
Kell–blood-group antigens, including k (Cellano), Kpb
(Rautenberg), and Ku (Peltz or antitotal Kell) (Redman
and Marsh 1993). Importantly, the phenotype is com-
pletely distinct from the very common Kell-negative and
the extremely rare Kell-null blood groups. When trans-
fused, McLeod-phenotype patients may respond with
anti-Kx and anti-Km antibodies, rendering future trans-
fusion extremely difficult. For this reason, X-linked
CGD patients, particularly those with deletion muta-
tions, should be screened for the McLeod phenotype by
quantitative determination of k, Kpb, and Ku expression.
The missense mutations are shown in figure 1, mapped
onto a representation of the gp91-phox molecule and
its putative functional domains. The transmembrane do-
mains and orientation of the amino terminus are based
on current and past mutation data, hydropathy plots,
and previous (Imajoh-Ohmi et al. 1992; Burritt et al.
1995) and current (A. R. Cross, M. C. Dinauer, and J.
T. Curnutte, unpublished data) studies with blocking
peptides and antipeptide antibodies; putative flavine-ad-
enine dinucleotide (FAD)– and NADPH-binding regions
and glycosylation sites are based on gp91-phox struc-
tural analyses by A. W. Segal’s laboratory (Segal et al.
1992; Wallach and Segal 1997). Three regions of the
molecule show clusters of mutations. Seventeen of the
30 missense mutations are located within three short
(15–31 amino acids) sequences (table 4 and fig. 1): five
kindreds have mutations at amino acids 209–223 (en-
coded in exon 6); five kindreds showmutations at amino
acids 309–339 (encoded in exon 9); and sevenmutations
are located at amino acids 405–422 (encoded in exon
10). Similarly, a recent review of CGD mutations from
multiple sources located 15 of 30 independent missense
mutations in exons 9 and 10 of CYBB (Roos et al.
1996b). However, as discussed below, these exons do
not constitute hot spots for other types of mutations.
Three of the histidines that constitute potential heme-
binding sites are altered by missense mutations. Those
tested for biochemical function showed no residual
oxidase activity or cytochrome b protein, as was ex-
pected from the critical role of heme incorporation in
the formation and stability of the cytochrome b heter-
odimer (Yu et al. 1997). In contrast, several mutations
of proline moieties showed partial or complete preser-
vation of cytochrome b protein (but no function), despite
the presumed role of this amino acid in the formation
of bends in secondary structure. In fact, a surprising
40% (7 of 17) of the missense mutations evaluated for
biochemical function showed some preservation of ei-
ther superoxide generation or cytochrome b protein.
Thus, the gp91-phox molecule is highly susceptible to
mutational damage, but not every change is a knockout.
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Figure 2 Heterogeneity in positions of CYBB mutations causing X-linked CGD. Each arrow represents a single kindred; the type of
arrowhead indicates the type of mutation (as defined in the key [bottom right]). Stacked vertical arrows represent multiple unrelated kindreds
with mutations at the same location. Solid horizontal lines indicate deletion mutations; their lengths map the sizes of the deletions. Arrowheads
on the horizontal lines represent unknown deletion length in the direction of the arrow.
Mutations that interfere with normal splicing of nu-
clear RNA transcripts also contribute to the spectrum
of X-linked CGD genotypes. Although the majority di-
rectly altered the splice junctions, several mutations oc-
curred at locations X8 nt upstream or downstream. The
largely abnormal splicing of these transcripts shows, as
has been noted previously in other genes (Reed andMan-
iatis 1986; Carothers et al. 1993), that splice-site selec-
tion can be affected by mutations of either the exon
sequence just proximal to the 5′ splice junction or the
intron sequence more distal to the splice site.
Only two kindreds showed regulatory-region muta-
tions. We limited sequencing to the proximal 5′ flanking
region, the exons, and the intron boundaries; therefore,
potential regulatory elements in more distal upstream,
downstream, or intronic locations would have escaped
discovery. The detection of mutations in all 131 kindreds
indicates that genotypes causing aberrant gene regula-
tion are very rare or that the resultant phenotypes are
too mild for diagnosis of CGD.
The heterogeneity of mutations detected in this study
and the lack of any predominant genotype indicate that
the worldwide incidence of the disease represents many
different mutational events, without any evidence for a
founder effect. Such a pattern is expected for a disorder
with a phenotype of a severe immune-system defect and
recurrent infections. From an evolutionary point of view,
the originally described “fatal granulomatous disease of
childhood” (Bridges et al. 1959; Holmes et al. 1966) has
only very recently become a chronic disease with life
expectancy extending into adulthood (Mouy et al. 1989;
Finn et al. 1990).
The heterogeneity of mutations in X-linked CGD con-
trasts dramatically with the mutation pattern in CGD
due to deficiency of p47-phox. Studies from the United
States, Europe, and Japan (Casimir et al. 1991; Volpp
and Lin 1993; Iwata et al. 1994) have demonstrated the
same genetic defect, a frameshift due to a GT deletion
in exon 2, in 19 alleles from 10 patients. A highly ho-
mologous p47-phox pseudogene contains the same de-
fect, suggesting that recombination between the wild-
type gene and the pseudogene is a common mutational
event. Defects in p22-phox or p67-phox appear to arise
from heterogeneous mutations (Roos et al. 1996b), but
very few molecular analyses have been performed for
these rarest forms of autosomal recessive CGD.
In addition to the wide variety of mechanisms for the
observed mutations, their distribution within the CYBB
gene also exhibits great heterogeneity. As shown in figure
2, loci are dispersed throughout the 13 exons and their
intron boundaries. A similar broad distribution was re-
ported in the review by Roos et al. (1996b). Thus, no
mutational hot spots appear to affect this gene. In ad-
dition, the complete sequencing of 150 CYBB genes, in
patients and carriers, showed only the one known cod-
ing-region polymorphism (Kuribayashi et al. 1996). Al-
though many more genes will need to be sequenced to
determine the true frequency of polymorphisms, their
rarity in this series and in the current literature suggests
that the gp91-phox molecule does not tolerate most mi-
nor alterations in structure. Even in the genomic DNA
of the gene, there is a remarkable paucity of RFLPs.
Thus, most mutations in the CYBB gene appear to pro-
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duce biochemically significant changes and clinical
CGD.
Carrier detection for this X-linked disorder revealed
the mutated gene or a functionally abnormal phagocyte
population in 89% of mothers. The apparent sponta-
neous-mutation rate of ∼11% falls well belowHaldane’s
calculation that one-third of cases of X-linked disorders
represent new mutations if the population is at equilib-
rium and the viability or fertility of the affected males
is very low (Haldane 1935). The difference probably
reflects the well-known effects of genetic drift and re-
productive compensation (Lange et al. 1978), as well as
some degree of selection bias due to the inclusion, in our
series, of carrier mothers referred for prenatal diagnosis
of CGD and to the higher likelihood that a referring
physician would consider the diagnosis of CGD for a
patient with a positive family history.
This molecular analysis of a large series of kindreds
with X-linked CGD provides insight into the breadth
and relative distribution of mutations responsible for the
disease. Further detection of missense mutations and
pooling of data from other studies should also permit
the dissection of the gp91-phox molecule. These “ex-
periments of nature,” in combination with structural
modeling and site-directed mutagenesis, eventually
should elucidate the relationship between the structure
and the function of this key component of the respira-
tory-burst oxidase.
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